Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-751,871 plus paclitaxel and carboplatin vs paclitaxel and carboplatin in non-small cell lung cancer
2008-000345-55Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of figitumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Mar 2008; status: completed.
02
Drugs
figitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-000345-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000345-55.